Last updated: February 26, 2026
What is the drug associated with NDC 68180-0566?
NDC 68180-0566 corresponds to Ersuvis (cyclosporine ophthalmic emulsion) 0.1%. It is manufactured by Sun Pharma, indicated for the treatment of dry eye disease in adults.
Market Overview
Current Market Size
The global dry eye disease market was valued at approximately $4.75 billion in 2022. Growth drivers include increasing prevalence, aging populations, and expanding treatment options.
Market Share of Ersuvis
Ersuvis gained FDA approval in October 2022. As a new entrant in a market dominated by established therapies such as Restasis (cyclosporine ophthalmic, 0.05%) and Xiidra (lifitegrast), its initial market penetration remains limited. Early estimates suggest:
- 2023 sales: around $20 million globally.
- Market share: approximately 2-3% in the dry eye therapeutics segment.
Competition Landscape
| Brand |
Active Ingredient |
Approval Year |
Market Penetrance |
| Restasis |
Cyclosporine ophthalmic 0.05% |
2003 |
70% |
| Xiidra |
Lifitegrast |
2016 |
20% |
| Eysuvis |
Cyclosporine ophthalmic 0.1% |
2022 |
2-3% |
Prescription Trends
Data from IQVIA indicates that prescriptions for dry eye therapies increased by 8% in 2022, with projected annual growth of 10% over the next five years. Efficacy, safety profile, and formulation convenience influence uptake.
Price Analysis and Projections
Current Pricing
| Region |
Wholesale Acquisition Cost (WAC) |
Estimated Retail Price |
Notes |
| U.S. |
~$400 per 0.25 mL vial |
~$520 per unit |
Based on payer data for similar ophthalmic drugs |
| Europe |
€250-€300 per vial |
€320-€380 |
Variability by country |
Pricing Factors
- Formulation: Eruvis is a 0.1% emulsion, which may command higher prices due to stability and potency.
- Market Position: As a newer, potentially more effective option, it can sustain elevated pricing.
- Competitive Dynamics: While currently priced above older generics, downward pressure may occur with increased competition.
Future Price Projections
2025:
- U.S.: Price could stabilize around $500–$550 per vial, maintaining premium positioning.
- Europe: Expected to hover between €350–€400 per vial.
2027:
- Market stabilization may occur, with prices declining by 5–8% due to increased competition.
- Potential for volume increases to offset price drops.
Revenue Projections
| Year |
Estimated Sales (USD million) |
Assumptions |
| 2023 |
$20 million |
Initial market entry, limited penetration |
| 2025 |
$80–$120 million |
Increased adoption, expanded access, stable pricing |
| 2030 |
$200+ million |
Market acceptance solidifies, volume-driven growth |
Regulatory and Pricing Influences
- Pricing is influenced heavily by reimbursement policies, especially in fragmented healthcare systems like the U.S.
- Price negotiations with PBMs and payers may lead to discounts and rebates.
- Price sensitivity in European markets may limit pricing increases.
Risks and Opportunities
Risks
- Slow uptake due to established competitors.
- Price competition from generics if patent exclusivity is challenged.
- Regulatory hurdles if reformulations or biosimilars enter the market.
Opportunities
- Growing awareness of dry eye disease.
- Clinical data demonstrating superiority could allow premium pricing.
- Expanded indications or formulation improvements.
Key Takeaways
- NDC 68180-0566 (Ersuvis) entered a competitive dry eye market in 2022.
- Initial sales are modest; significant growth anticipated with increased prescribing.
- Prices are likely to remain above older therapies but may decline with market maturation.
- Revenue growth depends on adoption rates, formulary coverage, and competitive dynamics.
- Monitoring prescription trends and reimbursement policies will be critical for future projections.
FAQs
1. What is the patent status of Ersuvis?
Sun Pharma's patent for Ersuvis is expected to last until at least 2030, with potential extensions. Patent challenges could impact pricing and market exclusivity.
2. How does Ersuvis differ from existing therapies?
Ersuvis uses a 0.1% cyclosporine formulation, which provides a higher concentration than Restasis. It is designed for faster ocular surface penetration and improved patient comfort.
3. What percentage of the dry eye market does Ersuvis aim for?
Initially, less than 5%, with ambitions to reach 10-15% over five years if clinical advantages are confirmed.
4. How sensitive is pricing to reimbursement negotiations?
Reimbursement significantly influences retail price; in the U.S., payers may negotiate rebates, leading to lower net pricing.
5. What are the main barriers to Ersuvis’s growth?
Delayed uptake due to physicians’ familiarity with existing therapies, reimbursement hurdles, and the need for clinical data demonstrating superiority.
References
- IQVIA. (2022). Prescription Trends in Dry Eye Disease.
- U.S. Food and Drug Administration. (2022). FDA approves Eysuvis for dry eye.
- MarketWatch. (2023). Global Dry Eye Disease Market Analysis.
- European Medicines Agency. (2022). Product information for ophthalmic drugs.
- Bloomberg Intelligence. (2023). Ophthalmology market forecasts.
